via

Avian (Bird) Flu: Is There a Role for Rapid Tests?

With human infections of bird flu (avian influenza) reported in Asia and Eastern Europe, public health officials have moved swiftly to develop policies on surveillance, diagnosis, and treatment. The virus in question is the H5N1 subtype of influenza A, which has become epidemic...

ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 2, 2007 - ViaCell, Inc.(NASDAQ: VIAC) today announced that Marc D. Beer, President andChief Executive Officer of ViaCell, will present an update on itsbusiness activities and product pipeline at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference on Tuesday, July10, 2007 at 3:00 p.m. at the Mandarin Oriental Hotel in New York,NY. A live...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking datapresented at the American Diabetes Association (ADA) 67th AnnualScientific Sessions showed that, when used investigationally asinitial therapy, JANUVIA(TM) (sitagliptin) in combination withmetformin provided significant glycemic improvement and wasgenerally well tolerated over 54 weeks in patients with type 2diabetes. Additional new...

Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting

Company-Sponsored Investor Briefing and Webcast to FollowPresentation DANBURY, Conn., June 20, 2007 /PRNewswire-FirstCall/ -- BiodelInc. today announced plans to present clinical results of itsleading product candidate, VIAject(TM), at the 67th Annual AmericanDiabetes Association (ADA) Scientific Sessions, to be held inChicago, June 22 through June 26. Biodel's oral presentation at...

AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIRPharmaceuticals (NASDAQ:AVNR) today announced the presentation ofPhase III data, including efficacy, safety and improvements inpatient-centered outcomes in patients with diabetic peripheralneuropathic (DPN) pain treated with the investigational drugZenvia(TM) (dextromethorphan/quinidine (DM/Q)), an NMDA receptorantagonist and sigma-1...

Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Hemispherx Biopharma, Inc.(AMEX: HEB), a biopharmaceutical company engaged in the clinicaldevelopment of new drug entities for the treatment of pandemicdisease threats, announced today a new scientific report on theactivity of its experimental therapeutic Ampligen(R) in combinationwith approved anti-influenza agents against highly pathogenic avianinflue...

Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference

PARIS--(BUSINESS WIRE)--May 31, 2007 - Hemispherx Biopharma, Inc.(AMEX: HEB), a biopharmaceutical company engaged in the clinicaldevelopment and manufacture of new drug entities for pandemicdisease threats, announced today a new scientific report featuringits antiviral therapeutic product candidate Alferon-LDO incombating highly pathogenic avian influenza (HPAI), also known as"bird flu." Al...

CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals

VIENNA, Va., May 23, 2007 /PRNewswire-FirstCall/ -- CEL-SCICORPORATION announces that CEL-1000 increased the immune responseagainst H5 avian influenza antigen in combination with MAS-1, awater-in-oil adjuvant delivery system. These findings werepresented on May 23, 2007 by Dr. Daniel Zimmerman, Senior VicePresident of Research, Cellular Immunology at CEL-SCI at theAmerican Society of Mic...

AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 8, 2007 - AVANIRPharmaceuticals (NASDAQ:AVNR) today announced Phase III data on theefficacy, safety and improvements in patient-centered outcomes inpatients with diabetic peripheral neuropathic (DPN) pain treatedwith the investigational drug Zenvia(TM) (dextromethorphan /quinidine) will be presented in two scientific posters at theSecond Internation...

NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus

WEST HAVEN, Conn.--(BUSINESS WIRE)--May 7, 2007 - NanoViricides,Inc. (Pink Sheets: NNVC) presented results of recent animal studiesagainst rabies and BSL3 in vitro studies against a Clade 2 H5N1(avian influenza) virus at the 23rd Annual Symposium of the PanAmerican Society for Clinical Virology in Tampa, FL, on Wednesday,May 2. (Pan American Society for Clinical Virology (PASCV):Clinical Vi...

St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

BioCryst Says Study Confirms and Extends Evidence Seen in aPrevious Study BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ --BioCryst Pharmaceuticals, Inc. today announced that investigatorsat St. Jude Children's Research Hospital, Memphis, TN, reportedfavorable results evaluating peramivir treatment in an animal modelof influenza using a highly virulent strain of H5N1 virus (an avia...

Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 1, 2007 - AvanirPharmaceuticals (NASDAQ:AVNR) today announced that data on thelong-term safety of the investigational drug Zenvia(TM)(dextromethorphan / quinidine) and the prevalence of InvoluntaryEmotional Expression Disorder (IEED) were presented today during aposter session at the American Academy of Neurology (AAN) 59thAnnual Meeting in Boston....

Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 18, 2007 - AvanirPharmaceuticals (NASDAQ:AVNR) today announced positive top-lineresults from the company's Phase III clinical trial evaluating theinvestigational drug Zenvia(TM) (dextromethorphanhydrobromide/quinidine sulfate ("DMQ")), an NMDA antagonist andsigma-1 agonist, in diabetic neuropathic pain. The primary endpoint of the trial was based...

CytoGenix Announces Successful Testing of synDNA Vaccine for Avian Influenza Virus

HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. (CYGX.OB)announced today that it has successfully completed an importantpilot study with a novel synDNA(TM) vaccine designed for humans(therapeutic) and intended to protect against the avian (H5N1)influenza virus. The study clearly demonstrated a robust protectiveeffect in mice treated with the Company's synDNA(TM) vaccinewhereas all t...